Ligand Pharmaceuticals (LGND) Net Income Growth (5y) (2015 - 2026)

Ligand Pharmaceuticals (LGND) Net Income Growth (5y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Ligand Pharmaceuticals 5.92 Bn 5.14 Bn 48.45 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -23.42%
Dec 31, 2025 20.55%
Sep 30, 2025 81.14%
Jun 30, 2025 -26.16%
Mar 31, 2025 -11.96%
Dec 31, 2024 -33.38%
Mar 31, 2023 -15.29%
Mar 31, 2021 -43.53%
Dec 31, 2020 22.63%
Sep 30, 2020 -15.25%
Jun 30, 2018 98.12%
Mar 31, 2018 198.52%
Mar 31, 2016 209.67%
Dec 31, 2015 26.25%
Sep 30, 2015 610.50%